BetterLife Pharma (TSE:BETR)
:BETR
Want to see TSE:BETR full AI Analyst Report?
Top Page
BetterLife Pharma
(BETR)
Select Model
Select Model
Rating:52Neutral
Price Target:
C$0.09
▲(115.00% Upside)
Action:ReiteratedDate:03/07/26
The score is held back primarily by fragile financials (no revenue, ongoing losses, negative equity), partially offset by improving recent cash burn/loss trends. Technicals are the main positive with clear upward price momentum, while valuation provides limited support due to negative earnings and no dividend.
Positive Factors
Improving cash burn
Operating cash outflow has narrowed materially, indicating the company reduced discretionary spending or optimized operations. This durable reduction extends runway and lowers near-term financing pressure, improving odds of advancing clinical programs over the next several quarters.
Negative Factors
No revenue
Absence of product revenue means the business remains fully pre-revenue and dependent on financing for operations. That limits visibility into commercial viability and means sustaining R&D and development timelines requires continued capital access over many quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving cash burn
Operating cash outflow has narrowed materially, indicating the company reduced discretionary spending or optimized operations. This durable reduction extends runway and lowers near-term financing pressure, improving odds of advancing clinical programs over the next several quarters.
Read all positive factors
BetterLife Pharma (BETR) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$9.87M
Dividend YieldN/A
Average Volume (3M)121.96K
Price to Earnings (P/E)―
Beta (1Y)-0.27
Revenue GrowthN/A
EPS Growth62.43%
CountryCA
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding151,896,680
10 Day Avg. Volume118,740
30 Day Avg. Volume121,961
Financial Highlights & Ratios
PEG Ratio-0.60
Price to Book (P/B)-1.51
Price to Sales (P/S)0.00
P/FCF Ratio-7.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BetterLife Pharma Business Overview & Revenue Model
Company Description
BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of neurological disorders in Canada and internationally. It is involved in refining and developing drug candidates fro...
How the Company Makes Money
BetterLife Pharma makes money primarily through the development and commercialization of its therapeutic products. The company's revenue model is based on the successful advancement of its drug candidates through clinical trials and obtaining regu...
BetterLife Pharma Financial Statement Overview
Summary
Income Statement
10
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -18.43K | -18.44K | ― |
| EBITDA | -1.79M | 0.00 | -3.19M | -9.24M | -11.92M | -7.61M |
| Net Income | -1.85M | -3.52M | -2.89M | -9.02M | -12.16M | -36.35M |
Balance Sheet | ||||||
| Total Assets | 291.13K | 224.96K | 324.75K | 74.73K | 1.16M | 1.34M |
| Cash, Cash Equivalents and Short-Term Investments | 7.96K | 8.18K | 37.38K | 8.31K | 173.51K | 154.72K |
| Total Debt | 659.63K | 1.30M | 1.47M | 1.19M | 1.40M | 500.00K |
| Total Liabilities | 6.46M | 7.59M | 8.02M | 7.61M | 5.04M | 5.95M |
| Stockholders Equity | -9.46M | -10.68M | -10.81M | -10.73M | -3.88M | -4.61M |
Cash Flow | ||||||
| Free Cash Flow | -217.62K | -2.02M | -2.47M | -1.50M | -11.20M | -7.26M |
| Operating Cash Flow | -217.61K | -2.02M | -2.47M | -1.50M | -11.20M | -7.16M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 165.04K | -18.77K | -71.55K |
| Financing Cash Flow | 206.94K | 1.99M | 2.50M | 1.34M | 11.23M | 4.09M |
BetterLife Pharma Technical Analysis
Negative
0.04
Price Trends
0.06
Negative
0.06
Positive
0.07
Negative
Market Momentum
>-0.01
Positive
42.46
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BETR, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and below the 200-day MA of 0.07, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.46 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BETR.
BetterLife Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | C$9.87M | -6.03 | 19.14% | ― | ― | 62.43% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$15.24M | -7.66 | -78.88% | ― | 125.00% | 25.37% | |
47 Neutral | C$10.71M | -6.62 | 64.41% | ― | ― | -3.16% | |
46 Neutral | C$7.74M | -721.61 | -112.32% | ― | ― | 26.95% | |
42 Neutral | C$4.97M | -4.13 | -41.36% | ― | 32.90% | -106.00% |
* Healthcare Sector Average
TSE:BETR
BetterLife Pharma
0.07
-0.02
-27.78%
TSE:CSCI
COSCIENS Biopharma
2.70
-2.40
-47.06%
TSE:PHRM
PharmaTher Holdings Ltd
0.09
-0.12
-59.52%
TSE:MRVL
Marvel Biosciences Corp
0.17
0.08
94.12%
TSE:MOOD
Doseology Sciences
0.62
0.22
55.00%
TSE:MDMA
PharmAla Biotech Holdings, Inc.
0.14
-0.01
-9.68%
BetterLife Pharma Corporate Events
Business Operations and StrategyExecutive/Board Changes
BetterLife Pharma Grants 6.05 Million Stock Options to Insiders
Positive
Feb 24, 2026
BetterLife Pharma has granted 6,050,000 stock options to its directors, officers and employees, each exercisable at $0.055 per share over five years and vesting in four equal tranches from the grant date through 18 months. The move underscores the...
Business Operations and Strategy
BetterLife Pharma Targets Global Partners for BETR-001 at JPM Week Forums
Positive
Jan 6, 2026
BetterLife Pharma said it will participate in the YAFO Capital Access Asia 2025 Partnering Forum during JPM Week in San Francisco, positioning the company to meet investors, pharmaceutical partners and strategic advisors from North America and Asi...
Business Operations and StrategyExecutive/Board Changes
BetterLife Pharma Director and Audit Chair Robert Metcalfe Resigns
Neutral
Dec 24, 2025
BetterLife Pharma Inc. has announced the resignation of Robert Metcalfe from its board of directors, where he served for six years and chaired the audit committee, marking a notable change in the company’s governance structure. Chief executi...
Business Operations and StrategyProduct-Related Announcements
BetterLife Pharma Partners with YAFO Capital for BETR-001 Expansion in Greater China
Positive
Dec 11, 2025
BetterLife Pharma has engaged Shanghai-based YAFO Capital as its exclusive advisor to seek strategic partnerships for the development of its proprietary BETR-001 in the Greater China regions. This collaboration aims to leverage YAFO’s expert...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.